Loading clinical trials...
Loading clinical trials...
A Phase IV, Open-label, Prospective Observational Study to Evaluate Virological Response in Antiretroviral-Experienced HIV 1 Infected Subjects Switching to Atripla (Efavirenz/Emtricitabine/Tenofovir DF) on an Empty Stomach
Conditions
Interventions
Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg
Locations
1
United Kingdom
Gilead Sciences
Cambridge, United Kingdom
Start Date
April 1, 2008
Primary Completion Date
November 1, 2010
Completion Date
December 1, 2010
Last Updated
November 21, 2011
NCT04142047
NCT06694805
NCT07428330
NCT07225530
NCT06665646
NCT05897099
Lead Sponsor
Gilead Sciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions